Abstract 1013
Background
Carcinoma of unknown primary (CUP) is a heterogeneous entity of malignant epithelial tumors. In general, CUP follows an aggressive biological and clinical behavior. There is generally limited information regarding this issue.
Methods
All patients categorized as having CUP who attended the department of clinical oncology, Menoufia University from January 2013 to December 2015 were included in the study. The patients’ features, investigations and clinical outcomes were collected. Also, time to progression (TTP) and overall survival (OS) were calculated.
Results
The study included 103 patients representing about 2.2% of the total number of patients visited clinical oncology department outpatients’ clinic during the same period. Most of the patients were males, the mean age of the patients was 58 years, pain was the most common presenting symptom, and adenocarcinoma was the most common reported pathological subtype. Only 50.5% of the patients were fit to receive platinum combination chemotherapy. The median TTP was 2 months and the median OS was 3 months. Age, performance status & presenting symptom had statistically significant relation with TTP. While, the baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.
Conclusions
Carcinomas of unknown primary origin are not uncommon tumors in clinical oncology department, Menoufia University with wide varieties of clinical presentations. Baseline performance status, presenting symptoms and pathological subtype had statistically significant relation with OS.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1310 - Upgrade of Low Grade Ductal Carcinoma in situ (DCIS): multimodality approach in a 10-year single institution study
Presenter: Ajung Chu
Session: Poster display - Cocktail
Resources:
Abstract
489 - Correlation between circulating tumor cells and the aromatase inhibitors therapy in postoperative patients with early breast cancer.
Presenter: Yumei Shi
Session: Poster display - Cocktail
Resources:
Abstract
838 - A Pilot Study of Single Pegfilgrastim Compared with Intermittent Every Other Days of 5 Shot-filgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Chemotherapy (G-CSF 105 trial: NCT02685111)
Presenter: Jaeho Jeong
Session: Poster display - Cocktail
Resources:
Abstract
1337 - Painful scalp during chemotherapy induced hair loss is associated to permanent alopecia in breast cancer patients
Presenter: Nesrine Mejri
Session: Poster display - Cocktail
Resources:
Abstract
1445 - Breast cancer survival analysis in East Azerbaijan: five years cancer registry data in Iran
Presenter: Shima Pashaei
Session: Poster display - Cocktail
Resources:
Abstract
1457 - Is sarcopenia associated with increased toxicity of neoadjuvant/adjuvant chemotherapy for breast cancer?
Presenter: Ayako Ueno
Session: Poster display - Cocktail
Resources:
Abstract
759 - A Study on possibility of High Sensitivity C - reactive protein (hs-CRP) and Circulating Interluekin-6 (IL-6) as biomarker in Breast Cancer Patients
Presenter: Md Shah Jalalur Rahman Shahi
Session: Poster display - Cocktail
Resources:
Abstract
1447 - Correlation Between Expression of Topoisomerase II Alpha with Ki-67 and Tumor Size in Luminal B-Like Indonesian Breast Cancer Patients
Presenter: Helenia Putri
Session: Poster display - Cocktail
Resources:
Abstract
1175 - Association of Serum Vitamin D Level and Vitamin D Receptor Polymorphism (Apa 1) And Breast Cancer
Presenter: Suzy Gohar
Session: Poster display - Cocktail
Resources:
Abstract
911 - Prognostic Nomograms for Predicting Overall and Cancer-Specific Survival in Breast Cancer Patients Not Achieving Pathological Complete Response After Neoadjuvant Chemotherapy
Presenter: Jianguo Lai
Session: Poster display - Cocktail
Resources:
Abstract